Elias T. Zambidis

Elias T. Zambidis

Pediatrics

Bloomberg 11N
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis.

HLHRUXO: a prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis.

Journal: Blood advances

Published: February 27, 2026

HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis.

HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis.

Journal: Blood advances

Published: February 27, 2026

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

PT/Cy-based alloBMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Journal: Blood advances

Published: January 05, 2026

PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

PTCy-based allo-BMT platform as a curative, accessible alternative for pediatric and young adult severe aplastic anemia.

Journal: Blood advances

Published: January 05, 2026

Defined Xenofree Reprogramming of Cord Blood Progenitors to Induced Pluripotent and Blastomere-Like Stem Cells.

Defined Xenofree Reprogramming of Cord Blood Progenitors to Induced Pluripotent and Blastomere-Like Stem Cells.

Journal: Journal of visualized experiments : JoVE

Published: September 08, 2025

Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.

Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.

Journal: Transplantation and cellular therapy

Published: August 19, 2025

Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.

Post-transplant Cyclophosphamide (PTCy) for HLA-Matched Hematopoietic Stem Cell Transplant (HCT) in Pediatric and Young Adult Patients with Hematologic Malignancies.

Journal: Transplantation and cellular therapy

Published: August 19, 2025

Human embryo research: how to move towards a 28-day limit.

Human embryo research: how to move towards a 28-day limit.

Journal: Nature

Published: July 02, 2025

Proteogenomic Reprogramming to a Functional Human Totipotent Stem Cell State via a PARP-DUX4 Regulatory Axis.

Proteogenomic Reprogramming to a Functional Human Totipotent Stem Cell State via a PARP-DUX4 Regulatory Axis.

Journal: bioRxiv : the preprint server for biology

Published: June 25, 2024

Proteogenomic reprogramming to a functional human blastomere-like stem cell state via a PARP-DUX4 regulatory axis.

Proteogenomic reprogramming to a functional human blastomere-like stem cell state via a PARP-DUX4 regulatory axis.

Journal: Cell reports

Published: April 15, 2024

Designing Chimeric Antigen Receptors for Myeloid Immune Cells.

Designing Chimeric Antigen Receptors for Myeloid Immune Cells.

Journal: Journal of cancer biology & research

Published: January 01, 2024

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Journal: Nature communications

Published: August 05, 2023

Showing 1-12 of 57

Last Updated: 09/26/2026